STAT+: FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm
WASHINGTON — The Food and Drug Administration has been without a permanent commissioner for six months. The agency is facing a barrage of criticisms over its approval of an as-yet-unproven Alzheimer’s drug. And now critics are calling for the ouster of the acting commissioner.
But speaking to that acting FDA Commissioner, longtime agency vet Janet Woodcock, you’d think everything is peachy.
